A solid body of evidence validates prediction of chemotherapy benefit
Strongly associated with the rate of distant recurrence
A low score indicating a significantly lower rate of distant recurrence and a lower likelihood of chemotherapy benefit6,7
Predictive for likelihood of benefit from chemotherapy
A high score indicating a higher rate of distant recurrence and predicting a significant benefit from chemotherapy4,8
TAILORx + RxPONDER results elevate the Oncotype DX Breast Recurrence Score test to the next level of precision with the highest quality of evidence.
Clear, meaningful results for more impactful conversations with patients about the magnitude of chemotherapy benefit.
STANDARD OF CARE